Expression of the TGFβ type II receptor (TβRII) in breast cancer cells prevents tumor formation [81], while inactivating mutations or overexpression of a dominant negative form of the receptor abolish TGFβ tumor suppressive effects and increase tumorigenicity [82–84]. This evidence concerns the gene TGFBR2 and breast carcinoma.